You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
New Postpartum Depression Drug Could Be Hard To Access For Moms Most In Need
New Postpartum Depression Drug Could Be Hard To Access For Moms Most In Need toggle caption AleksandarNakic/Getty Images One in nine women in the United States suffer from depression after childbirth. For some women, postpartum depression is so bad that they struggle to care for their children and may even consider or attempt suicide. This week, the Food and Drug Administration approved a new drug that can help, the first drug approved specifically for postpartum depression. While researchers and clinici...
Sage Therapeutics CEO: Getting the first postpartum depression drug approved
Sage Therapeutics CEO: Getting the first postpartum depression drug approved 21 Mins Ago Jim Cramer talks with Sage Therapeutics CEO Jeff Jonas about the biopharma company's Zulresso drug for postpartum depression and how it could help mothers....
Sage Stock Pops on FDA Approval for Postpartum Depression Drug
Sage Therapeutics (NYSE: SAGE ) is popped yesterday on FDA approval of its postpartum depression drug — the first of its kind. So far, SAGE stock is up 3%, but this on the back of a more than 70% run up year-to-date in anticipation of the news. Source: Shutterstock Postpartum depression is a sometimes life-threatening condition that can happen before or after a woman gives birth to a child. In serious cases, she may harm herself or her child as a result. It is estimated that as many as one in nine women w...
Expected May 2, Pre-Market